Last reviewed 2026-04-22 · How we verify

Solifenacin PO

Solifenacin is a muscarinic M3 receptor antagonist that reduces bladder muscle contractions to treat overactive bladder.

Solifenacin is a muscarinic M3 receptor antagonist that reduces bladder muscle contractions to treat overactive bladder. Used for Overactive bladder with symptoms of urge incontinence, urgency, and frequency.

At a glance

Mechanism of action

Solifenacin selectively blocks M3 muscarinic acetylcholine receptors on the detrusor muscle of the bladder, reducing involuntary contractions and increasing bladder capacity. This anticholinergic action decreases urinary frequency, urgency, and incontinence episodes associated with overactive bladder syndrome.

Approved indications

• Overactive bladder with symptoms of urge incontinence, urgency, and frequency

Common side effects

• Dry mouth
• Constipation
• Blurred vision
• Urinary retention
• Headache

Key clinical trials

• Mirabegron, Propevirine, Solifenacin for Treatment of Lower Urinary Tract Symptoms During Intravesical BCG Instillation (PHASE3)
• Behavioral Modification and Vesicare Versus Vesicare Alone for Urge Incontinence in Patients With Overactive Bladder (PHASE3)
• Solifenacin Succinate Versus Placebo in Inner City Women Ages 20-45 With Overactive Bladder (PHASE4)
• Solifenacin Succinate (VESIcare) for the Treatment of Urinary Incontinence in Parkinson's Disease (PHASE4)
• Evaluation of Solifenacin in the Treatment of OAB Symptoms in Patients Who Have Successfully Undergone GreenLight Photoselective Vaporization of the Prostate (PVP) (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.